Investigation of the international comparability of population-based routine hospital data set derived comorbidity scores for patients with lung cancer

Margreet Lüchtenborg, Eva J A Morris, Daniela Tataru, Victoria H Coupland, Andrew Smith, Roger L Milne, Luc Te Marvelde, Deborah Baker, Jane Young, Donna Turner, Diane Nishri, Craig Earle, Lorraine Shack, Anna Gavin, Deirdre Fitzpatrick, Conan Donnelly, Yulan Lin, Bjørn Møller, David H Brewster, Andrew DeasDyfed W Huws, Ceri White, Janet Warlow, Jem Rashbass, Michael D Peake

Research output: Contribution to journalArticle

2 Citations (Scopus)
296 Downloads (Pure)

Abstract

INTRODUCTION: The International Cancer Benchmarking Partnership (ICBP) identified significant international differences in lung cancer survival. Differing levels of comorbid disease across ICBP countries has been suggested as a potential explanation of this variation but, to date, no studies have quantified its impact. This study investigated whether comparable, robust comorbidity scores can be derived from the different routine population-based cancer data sets available in the ICBP jurisdictions and, if so, use them to quantify international variation in comorbidity and determine its influence on outcome.

METHODS: Linked population-based lung cancer registry and hospital discharge data sets were acquired from nine ICBP jurisdictions in Australia, Canada, Norway and the UK providing a study population of 233 981 individuals. For each person in this cohort Charlson, Elixhauser and inpatient bed day Comorbidity Scores were derived relating to the 4-36 months prior to their lung cancer diagnosis. The scores were then compared to assess their validity and feasibility of use in international survival comparisons.

RESULTS: It was feasible to generate the three comorbidity scores for each jurisdiction, which were found to have good content, face and concurrent validity. Predictive validity was limited and there was evidence that the reliability was questionable.

CONCLUSION: The results presented here indicate that interjurisdictional comparability of recorded comorbidity was limited due to probable differences in coding and hospital admission practices in each area. Before the contribution of comorbidity on international differences in cancer survival can be investigated an internationally harmonised comorbidity index is required.

Original languageEnglish
Pages (from-to)339-349
Number of pages11
JournalThorax
Volume73
Issue number4
Early online date27 Oct 2017
DOIs
Publication statusEarly online date - 27 Oct 2017

Fingerprint Dive into the research topics of 'Investigation of the international comparability of population-based routine hospital data set derived comorbidity scores for patients with lung cancer'. Together they form a unique fingerprint.

  • Cite this

    Lüchtenborg, M., Morris, E. J. A., Tataru, D., Coupland, V. H., Smith, A., Milne, R. L., Te Marvelde, L., Baker, D., Young, J., Turner, D., Nishri, D., Earle, C., Shack, L., Gavin, A., Fitzpatrick, D., Donnelly, C., Lin, Y., Møller, B., Brewster, D. H., ... Peake, M. D. (2017). Investigation of the international comparability of population-based routine hospital data set derived comorbidity scores for patients with lung cancer. Thorax, 73(4), 339-349. https://doi.org/10.1136/thoraxjnl-2017-210362